Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.51 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.51 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.51 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18840494 | 0.94 | POLG (0.59) | POLGPOLBP2RY2P2RY6P2RY4 | |
| SCHEMBL18855468 | 0.94 | POLG (0.59) | POLGPOLBP2RY2P2RY6P2RY4 | |
| SCHEMBL18844327 | 0.94 | POLG (0.59) | POLGPOLBP2RY2P2RY6P2RY4 | |
| SCHEMBL18844322 | 0.94 | POLG (0.59) | POLGPOLBP2RY2P2RY6P2RY4 | |
| SCHEMBL22327467 | 0.89 | POLG (0.53) | POLGPOLBP2RY2P2RY6P2RY4 | |
| SCHEMBL23734154 | 0.86 | POLG (0.57) | POLGPOLBP2RY2P2RY6P2RY4 | |
| SCHEMBL21786933 | 0.86 | POLG (0.57) | POLGPOLBP2RY2P2RY6P2RY4 | |
| SCHEMBL23734249 | 0.86 | POLG (0.57) | POLGPOLBP2RY2P2RY6P2RY4 | |
| SCHEMBL21786852 | 0.84 | POLG (0.56) | POLGPOLBP2RY2P2RY6P2RY4 | |
| SCHEMBL21786801 | 0.84 | POLG (0.55) | POLGPOLBP2RY2P2RY6P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273539-B2 | Methods of using nucleotide analogues | QIAGEN SCIENCES, LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-20170137878-A1 | METHODS OF USING NUCLEOTIDE ANALOGUES | IsoPlexis Corporation | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273539-B2 | Methods of using nucleotide analogues | NT5C3B, SAMHD1, RNGTT | POLG 197/4885POLB 32/4885P2RY2 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.